Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma.
Hewson CA, Patel S, Calzetta L, Campwala H, Havard S, Luscombe E, Clarke PA, Peachell PT, Matera MG, Cazzola M, Page C, Abraham WM, Williams CM, Clark JD, Liu WL, Clarke NP, Yeadon M. Hewson CA, et al. Among authors: clarke np. J Pharmacol Exp Ther. 2012 Mar;340(3):656-65. doi: 10.1124/jpet.111.186379. Epub 2011 Dec 7. J Pharmacol Exp Ther. 2012. PMID: 22160268
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.
Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, Brown AD, Yeadon M, Perros-Huguet C, Trevethick MA, Clarke NP, Webster R, Jones RM, Burrows JL, Feeder N, Taylor SC, Spence FJ. Glossop PA, et al. Among authors: clarke np. J Med Chem. 2010 Sep 23;53(18):6640-52. doi: 10.1021/jm1005989. J Med Chem. 2010. PMID: 20804199
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
Glossop PA, Watson CA, Price DA, Bunnage ME, Middleton DS, Wood A, James K, Roberts D, Strang RS, Yeadon M, Perros-Huguet C, Clarke NP, Trevethick MA, Machin I, Stuart EF, Evans SM, Harrison AC, Fairman DA, Agoram B, Burrows JL, Feeder N, Fulton CK, Dillon BR, Entwistle DA, Spence FJ. Glossop PA, et al. Among authors: clarke np. J Med Chem. 2011 Oct 13;54(19):6888-904. doi: 10.1021/jm200884j. Epub 2011 Sep 20. J Med Chem. 2011. PMID: 21870878 Clinical Trial.
Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).
Masood MA, Selby MD, Bell AS, Mansfield AC, Gardner M, Smith GF, Lane C, Kenyon-Edwards H, Osborne R, Jones RM, Liu WL, Brown CD, Clarke N, Perrucio F, Mowbray CE. Masood MA, et al. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6591-5. doi: 10.1016/j.bmcl.2011.07.114. Epub 2011 Aug 27. Bioorg Med Chem Lett. 2011. PMID: 21955944
Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
Mowbray CE, Bell AS, Clarke NP, Collins M, Jones RM, Lane CA, Liu WL, Newman SD, Paradowski M, Schenck EJ, Selby MD, Swain NA, Williams DH. Mowbray CE, et al. Among authors: clarke np. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602. doi: 10.1016/j.bmcl.2011.07.125. Epub 2011 Aug 9. Bioorg Med Chem Lett. 2011. PMID: 21920751
Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
Jones LH, Burrows J, Feeder N, Glossop P, James K, Jones RM, Kenyon AS, Patel S, Roberts DF, Selby MD, Strang RS, Stuart EF, Trevethick MA, Watson J, Wright KN, Clarke N. Jones LH, et al. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5121-6. doi: 10.1016/j.bmcl.2015.10.008. Epub 2015 Oct 8. Bioorg Med Chem Lett. 2015. PMID: 26471092
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.
Jones LH, Baldock H, Bunnage ME, Burrows J, Clarke N, Coghlan M, Entwistle D, Fairman D, Feeder N, Fulton C, Hilton L, James K, Jones RM, Kenyon AS, Marshall S, Newman SD, Osborne R, Patel S, Selby MD, Stuart EF, Trevethick MA, Wright KN, Price DA. Jones LH, et al. Bioorg Med Chem Lett. 2011 May 1;21(9):2759-63. doi: 10.1016/j.bmcl.2010.10.132. Epub 2010 Oct 31. Bioorg Med Chem Lett. 2011. PMID: 21075627
Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.
Fray MJ, Fish PV, Allan GA, Bish G, Clarke N, Eccles R, Harrison AC, Le Net JL, Phillips SC, Regan N, Sobry C, Stobie A, Wakenhut F, Westbrook D, Westbrook SL, Whitlock GA. Fray MJ, et al. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. doi: 10.1016/j.bmcl.2010.04.052. Epub 2010 Apr 18. Bioorg Med Chem Lett. 2010. PMID: 20471260
51 results